12:25 PM EDT, 10/18/2024 (MT Newswires) -- Revance Therapeutics ( RVNC ) said Friday it has agreed with Crown Laboratories to further extend the deadline for Crown to acquire all outstanding Revance shares at $6.66 apiece in a tender offer, amid ongoing dispute with Teoxane.

Revance is still in discussions with Teoxane regarding claims that it breached a 2020 distribution agreement, under which Revance is the exclusive commercialization partner for Teoxane's dermal fillers.

Revance denies these allegationsand is actively defending its position.

The deadline buyout deadline has been extended to Oct. 25 and the ongoing discussions could result in further delays to the tender offer that will result in Revance becoming Crown subsidiary and no longer publicly traded on Nasdaq.

Price: 5.28, Change: +0.10, Percent Change: +1.83